Insights into HIV-1 Reverse Transcriptase (RT) Inhibition and Drug Resistance from Thirty Years of Structural Studies

Insights into HIV-1 Reverse Transcriptase (RT) Inhibition and Drug Resistance from Thirty Years of Structural Studies

The enzyme reverse transcriptase (RT) plays a central role in the life cycle of human immunodeficiency virus (HIV), and RT has been an important drug target. Elucidations of the RT structures trapping and detailing the enzyme at various functional and conformational states by X-ray crystallography h...

Descripció completa

Dades bibliogràfiques
Autors principals:	Abhimanyu K. Singh, Kalyan Das
Format:	Article
Idioma:	English
Publicat:	MDPI AG 2022-05-01
Col·lecció:	Viruses
Matèries:	HIV-RT NRTI NNRTI drug design structural biology crystallography
Accés en línia:	https://www.mdpi.com/1999-4915/14/5/1027

Ítems similars

Approved HIV reverse transcriptase inhibitors in the past decade
per: Guangdi Li, et al.
Publicat: (2022-04-01)

Mathematical Modelling of the Molecular Mechanisms of Interaction of Tenofovir with Emtricitabine against HIV
per: Sara Iannuzzi, et al.
Publicat: (2021-07-01)

The “Connection” Between HIV Drug Resistance and RNase H
per: Krista A. Delviks-Frankenberry, et al.
Publicat: (2010-07-01)

Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz + tenofovir + emtricitabine for HIV
per: Oliver T. Stirrup, et al.
Publicat: (2019-10-01)

Development of HIV Drug Resistance in a Cohort of Adults on First-Line Antiretroviral Therapy in Tanzania during the Stavudine Era
per: Raphael Z. Sangeda, et al.
Publicat: (2021-11-01)

Identification of a 3-aminoimidazo[1,2-a]pyridine inhibitor of HIV-1 reverse transcriptase
per: Elleder Daniel, et al.
Publicat: (2012-12-01)

Efficacy and safety of novel russian non-nucleoside reverse transcriptase inhibitor elsulfavirine in combination with 2 nucleoside/nucleotide reverse transcriptase inhibitors in first-line HIV treatment – 96-week study
per: A. V. Kravchenko, et al.
Publicat: (2018-07-01)

Diaryl ethers with carboxymethoxyphenacyl motif as potent HIV-1 reverse transcriptase inhibitors with improved solubility
per: Tomasz Frączek, et al.
Publicat: (2018-01-01)

APOBEC3 selects V179I in HIV-1 reverse transcriptase to provide selective advantage for non-nucleoside reverse transcriptase inhibitor-resistant mutants
per: Richa Dwivedi, et al.
Publicat: (2022-07-01)

Incidence and risk factors for neuropsychiatric events among Ghanaian HIV patients on long-term non-nucleoside reverse transcriptase inhibitor-based therapy
per: Fred S. Sarfo, et al.
Publicat: (2016-06-01)

Biophysical Insights into the Inhibitory Mechanism of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors
per: Nicolas Sluis-Cremer, et al.
Publicat: (2013-11-01)

Chronic Hepatitis B Treatment Strategies Using Polymerase Inhibitor-Based Combination Therapy
per: Eriko Ohsaki, et al.
Publicat: (2021-08-01)

Picomolar inhibitor of reverse transcriptase featuring significantly improved metabolic stability
per: Ya-Li Sang, et al.
Publicat: (2023-07-01)

The long-term outcomes of antiretroviral treatment initiated with mono or dual nucleoside reverse transcriptase inhibitors in HIV-1-infected children: an Asian observational study
per: Orasri Wittawatmongkol, et al.
Publicat: (2015-07-01)

Development of fluorine-substituted NH2-biphenyl-diarylpyrimidines as highly potent non-nucleoside reverse transcriptase inhibitors: Boosting the safety and metabolic stability
per: Xin Jin, et al.
Publicat: (2023-03-01)

Thymidine Analogue Mutations with M184V Significantly Decrease Phenotypic Susceptibility of HIV-1 Subtype C Reverse Transcriptase to Islatravir
per: Hyeonah Byun, et al.
Publicat: (2024-12-01)

Anti‐HIV drugs reduce risk of prediabetes and progression to type 2 diabetes in HIV‐infected patients
per: Joseph Magagnoli, et al.
Publicat: (2023-06-01)

Scaffold Hopping in Discovery of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: From CH(CN)-DABOs to CH(CN)-DAPYs
per: Ting-Ting Li, et al.
Publicat: (2020-03-01)

Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Induced Neuropathy and Mitochondrial Toxicity: Limitations of the Poly-γ Hypothesis and the Potential Roles of Autophagy and Drug Transport
per: John Haynes, et al.
Publicat: (2024-12-01)

The Lysine 65 Residue in HIV-1 Reverse Transcriptase Function and in Nucleoside Analog Drug Resistance
per: Scott J. Garforth, et al.
Publicat: (2014-10-01)

Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase
per: Stefan G. Sarafianos, et al.
Publicat: (2010-02-01)

Drug Resistance in Non-B Subtype HIV-1: Impact of HIV-1 Reverse Transcriptase Inhibitors
per: Kamalendra Singh, et al.
Publicat: (2014-09-01)

Risk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data
per: Oliver T. Stirrup, et al.
Publicat: (2018-04-01)

Evaluation of the HIV-1 drug resistance to elsulfavirine and the effectiveness of it among Russian treatment-naïve patients
per: A. A. Kirichenko, et al.
Publicat: (2021-01-01)

Global Conformational Dynamics of HIV-1 Reverse Transcriptase Bound to Non-Nucleoside Inhibitors
per: Peter V. Coveney, et al.
Publicat: (2012-07-01)

Drosophila model of anti-retroviral therapy induced peripheral neuropathy and nociceptive hypersensitivity
per: Keegan M. Bush, et al.
Publicat: (2021-01-01)

Nucleoside Analog 2′,3′-Isopropylidene-5-Iodouridine as Novel Efficient Inhibitor of HIV-1
per: Ksenia Glumakova, et al.
Publicat: (2023-09-01)

NNRTI-induced HIV-1 protease-mediated cytotoxicity induces rapid death of CD4 T cells during productive infection and latency reversal
per: Benjamin Trinité, et al.
Publicat: (2019-06-01)

HIV drug resistance prediction with weighted categorical kernel functions
per: Elies Ramon, et al.
Publicat: (2019-07-01)

HIV medication to prevent fetal infection during pregnancy
per: Teodora Gabriela Cioroba, et al.
Publicat: (2022-03-01)

High frequency of Lamivudine and Telbivudine resistance mutations in hepatitis B virus isolates from human immunodeficiency virus co-infected patients on highly active antiretroviral therapy in Bucaramanga, Colombia
per: Henry Bautista-Amorocho, et al.
Publicat: (2023-07-01)

Anthrarufin and Its Anionic Moieties as Potential Inhibitors of HIV-1 Reverse Transcriptase (RT)
per: Svetlana Jeremić, et al.
Publicat: (2022-11-01)

K103N, V106M and Y188L Significantly Reduce HIV-1 Subtype C Phenotypic Susceptibility to Doravirine
per: Nikita Reddy, et al.
Publicat: (2024-09-01)

Virulence and Replicative Fitness of HIV-1 Transmitted/Founder (T/F) Viruses Harbouring Drug Resistance-Associated Mutation
per: Aanand Sonawane, et al.
Publicat: (2024-11-01)

Machine learning aided multiscale modelling of the HIV-1 infection in the presence of NRTI therapy
per: Huseyin Tunc, et al.
Publicat: (2023-03-01)

Targeting the Structural Maturation Pathway of HIV-1 Reverse Transcriptase
per: Thomas W. Kirby, et al.
Publicat: (2023-11-01)

The Molecular Docking of Specific Reverse Transcriptase Inhibitory Ligands onto the Molecular Model of HIV-1 Reverse Transcriptase
per: Roohallah Yousefi
Publicat: (2024-06-01)

Virtual screening, molecular docking studies and DFT calculations of FDA approved compounds similar to the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz
per: Maryam A. Jordaan, et al.
Publicat: (2020-08-01)

Structure-Based Discovery and Characterization of a Preclinical Drug Candidate for the Treatment of HIV-1 Infection
per: Dongwei Kang, et al.
Publicat: (2022-10-01)

Transmitted drug resistance to rilpivirine among antiretroviral‐naïve patients living with HIV from northern Poland
per: Miłosz Parczewski, et al.
Publicat: (2014-01-01)